# Temporal dysregulation of PPARG-PRKAG2 co-expression in gray matter: Implications for cognitive decline and intervention targets in type 2 diabetes

**Authors:** Shelli R. Kesler, Kimberly A. Lewis, Heather Cuevas, Elena Flowers

PMC · DOI: 10.21203/rs.3.rs-7907793/v1 · Research Square · 2025-10-22

## TL;DR

This study finds that gene co-expression patterns in the brain change over time in people with type 2 diabetes, which may contribute to cognitive decline and dementia risk.

## Contribution

The study identifies a temporal dysregulation of PPARG-PRKAG2 co-expression in T2DM and its link to cognitive decline.

## Key findings

- PPARG and PRKAG2 co-expression was higher in early stages and weakened in later stages among T2DM patients.
- Co-expression was associated with cognitive function in controls but not in T2DM patients.
- T2DM patients not taking metformin showed unstable gene co-expression over time.

## Abstract

Type 2 diabetes mellitus (T2DM) is associated with increased risk for cognitive decline and diagnosis of Alzheimer’s disease (AD). The mechanisms of T2DM related dementia remain unclear.

Brain magnetic resonance imaging was retrospectively obtained for 1,802 adults (age 66 +/− 9 years, 47% male) of whom N = 271 had T2DM. We applied an accelerated longitudinal design and imaging transcriptomics to non-invasively examine the group-level trajectories of PPARGand PRKAG2 co-expression in gray matter.

Gene expression trajectories differed significantly between T2DM and controls (χ2 = 13.82, p = 0.001). Co-expression was higher in early stages and then weakened in later stages among T2DM, while remaining stable over time in controls. PPARG and PRKAG2 co-expression was significantly associated with cognitive function in controls (F = 3.17, p < 0.001) but not T2DM (F = 7.72, p = 0.299) suggesting dysregulated or failed compensatory mechanisms. Individuals with T2DM not taking metformin demonstrated unstable gene co-expression over time compared to those taking metformin (χ2 = 12.42, p = 0.006).

The convergence of PPARG-mediated metabolic remodeling and PRKAG2/AMPK-driven energy sensing may act as a coordinated neuroprotective mechanism, upregulated in response to cellular stress in both pathological (T2DM) and normative (aging) contexts. However, these processes appear to become dysregulated in T2DM, potentially resulting in cognitive decline and increased risk for dementia.

## Linked entities

- **Genes:** PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468], PRKAG2 (protein kinase AMP-activated non-catalytic subunit gamma 2) [NCBI Gene 51422]
- **Chemicals:** metformin (PubChem CID 4091)
- **Diseases:** type 2 diabetes mellitus (MONDO:0005148), Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** PRKAG2 (protein kinase AMP-activated non-catalytic subunit gamma 2) [NCBI Gene 51422] {aka AAKG, AAKG2, CMH6, GSDH, H91620p, WPWS}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 5563] {aka AMPK, AMPK2, AMPKa2, PRKAA}
- **Diseases:** AD (MESH:D000544), T2DM (MESH:D003924), dementia (MESH:D003704), cognitive decline (MESH:D003072)
- **Chemicals:** metformin (MESH:D008687)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12633498/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12633498/full.md

## References

57 references — full list in the complete paper: https://tomesphere.com/paper/PMC12633498/full.md

---
Source: https://tomesphere.com/paper/PMC12633498